Notice Number: NOT-AI-20-040
Release Date: March 25, 2020
The purpose of this Notice is to inform the extramural community that NOT-AI-20-030, “Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)” will be rescinded as of 04/08/2020 . NOT-AI-20-030 will be replaced by NOT-AI-20-034 for NIAID competitive revisions and NOT-GM-20-025 for NIGMS competitive revisions.
NIAID will replace NOT-AI-20-030 with NOT-AI-20-034 which uses a different funding opportunity announcement, PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Clinical Trial Optional)” for competitive revision application submissions in response to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) outbreak. NIAID applicants will have the option of applying to either NOT-AI-20-030 or NOT-AI-20-034 up until 04/08/2020 but are strongly encouraged to transition their application to NOT-AI-20-034 using the PA-20-135, “Emergency Competitive Revision to Existing NIH Awards (Clinical Trial Optional)” as soon as possible. However, NIAID will only accept applications to NOT-AI-20-034 after 04/08/2020. NIGMS will issue a new NOSI that will continue to use PA-18-935.
NIGMS will replace NOT-AI-20-030 with NOT-GM-20-025 which will continue to receive competitive revision applications to PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Clinical Trial Optional)”. NIGMS’s new Notice includes additional areas of interest related to SARS-CoV-2 and COVID-19 and will allow support of competitive revisions above the established dollar limits for the parent grant award. Please see NOT-GM-20-025 for more information. NIGMS applicants will have the option of applying to either NOT-AI-20-030 or NOT-GM-20-025 up until 04/08/2020 but are strongly encouraged to transition their application to NOT-GM-20-025 as soon as possible.
Please direct all inquiries to:
Diane Post, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Daniel E. Janes, Ph.D.
National Institute of General Medical Sciences (NIGMS)